Form 4: Keros Therapeutics Director Nima Farzan Receives Significant Equity Grant

Keros Therapeutics, Inc. Director Nima Farzan was granted 5,250 Restricted Stock Units and options to purchase 10,500 shares of common stock, aligning executive interests with shareholder value.

Summary

• Nima Farzan, a Director of Keros Therapeutics, Inc. (KROS), acquired 5,250 shares of Common Stock through a Restricted Stock Unit (RSU) award on June 4, 2025.
• The RSU award vests fully on the earlier of June 4, 2026, or the date of the Issuer's 2026 annual meeting of stockholders, contingent on continued service.
• Additionally, Mr. Farzan was granted stock options to purchase 10,500 shares of Common Stock with an exercise price of $14.82 per share on June 4, 2025.
• These stock options will vest in equal quarterly installments over the 12 months following the grant date, or fully by the Issuer's 2026 annual meeting of stockholders, subject to continued service.
• The stock options have an expiration date of June 3, 2035.

Sentiment

Score: 7

Explanation: The document reports a routine equity grant to a director, which is a positive for aligning interests but does not indicate significant operational or financial news that would dramatically alter the company's outlook. It reflects standard corporate governance and compensation practices.

Positives

• The grant of Restricted Stock Units and stock options to a director aligns their interests directly with those of the shareholders, incentivizing long-term performance and value creation.
• Equity compensation is a standard practice for attracting and retaining experienced board members.

Future Outlook

The future outlook, as indicated by the vesting schedules, suggests a commitment to retaining the director's service through at least the company's 2026 annual meeting, aligning their long-term incentives with the company's performance.

Industry Context

The granting of equity awards, such as Restricted Stock Units and stock options, to directors is a common and widely accepted practice across various industries, particularly in biotechnology and growth-oriented companies. This compensation structure is designed to align the interests of the board members with the long-term success and shareholder value of the company.

Comparison to Industry Standards

• Equity compensation for directors is a standard practice in the biotechnology sector, similar to companies like Biogen Inc. or Vertex Pharmaceuticals Inc., which frequently use stock-based awards to compensate their non-employee directors.
• The vesting schedules, tied to continued service and future annual meetings, are typical for director equity grants, ensuring ongoing commitment and oversight.
• The specific number of shares and exercise price would need to be compared against Keros Therapeutics' peer group and market capitalization to assess if it's above, below, or in line with industry averages for director compensation packages.

Corporate Governance

Stakeholder Impact

• Shareholders: Positive impact due to increased alignment of a director's interests with shareholder value through equity ownership.
• Employees: No direct impact mentioned, but a well-governed company with aligned leadership can indirectly benefit all employees.

Next Steps

• Continued service of Nima Farzan as a Director of Keros Therapeutics, Inc.
• Vesting of the 5,250 Restricted Stock Units on the earlier of June 4, 2026, or the 2026 annual meeting.
• Quarterly vesting of the 10,500 stock options over 12 months, or full vesting by the 2026 annual meeting.
• Potential exercise of stock options by Nima Farzan prior to their expiration on June 3, 2035.

Key Dates

Recommendation

Keywords

Keros Therapeutics, KROS, SEC Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Equity Grant, Director Compensation, Corporate Governance